PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsRNA-based nanodrug treats ovarian cancer in mice

BioNews

RNA-based nanodrug treats ovarian cancer in mice

Published 15 May 2023 posted in News and appears in BioNews 1189

Author

Jake Knox

PhD candidate, Institute of Child Health
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

An 80 percent ovarian cancer survival rate in mice has been achieved using an RNA-based drug to silence the expression of a protein crucial to cancer cell division...

An 80 percent ovarian cancer survival rate in mice has been achieved using an RNA-based drug to silence the expression of a protein crucial to cancer cell division.

Ovarian cancer is the eighth most common cancer worldwide and accounts for 4.7 percent of cancer deaths among women. Initial treatment of ovarian cancer involves surgery and chemotherapy; however, 80-85 percent of patients develop chemo-resistance. This means that developing new treatments that are unaffected by this resistance is crucial. Professor Dan Peer and his team at Tel Aviv University, Israel, have developed an RNA-based nanodrug to silence the expression of a protein responsible for cell division called CKAP5, and published the results of their study in Science Advances.

'We proved that CKAP5, a protein responsible for the cell's stability, can be silenced, and that this procedure collapses and destroys the entire cancer cell', said Dr Sushmita Chatterjee, post-doctoral researcher, and lead author on the study.

Messenger RNA, or mRNA, is needed to produce proteins from the genetic information contained in DNA. Small interfering RNA (siRNA) is capable of disrupting gene expression without altering the DNA itself as it binds to mRNA, stopping gene expression. In this study, researchers delivered siRNA into the tumour encased in lipid nanoparticles to silence this specific protein target and cause cancer cell death.

Researchers showed cancer cell death was due to the cells' inability to initiate certain stages of cell division, due to the loss of this crucial protein. They said their findings mean that the protein CKAP5 is a good potential target for further research into ovarian cancer treatments.

The team hopes to validate the high survival rates seen by using a patient-derived mouse model, and further investigate how this therapy interacts with other treatments, as targeted therapies often result in cancer resistance. Dr Chatterjee said they are also interested in understanding the impact of this treatment on late-stage ovarian cancers, 'since the majority of ovarian cancer patients are diagnosed at late stages, it will be also interesting to investigate the therapeutic effects of CKAP5 silencing in a metastasised/late-stage cancer model'.

Sources and References

  • 5 April 2023
    Science Advances
    Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells
  • Tel Aviv University
    Tel Aviv University researchers present new treatment for ovarian cancer
  • 27 April 2023
    Medical News Today
    Nanodrug treatment for ovarian cancer leads to 80 percent survival rate in animals

Related Articles

PET BioNews
News
21 June 2021 • 2 minutes read

Potential new approach identified for treating BRCA-related cancers

by Dr Christina Burke

A new class of drug could effectively treat types of breast, ovarian and prostate cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 May 2021 • 2 minutes read

PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations

by Dr Emma Bunting

New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...

PET BioNews
News
26 April 2021 • 2 minutes read

Olaparib extends life of ovarian cancer patients with BRCA1/2

by Hannah Flynn

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...

PET BioNews
News
4 May 2020 • 2 minutes read

Breast and ovarian cancer drug repurposed to treat prostate cancer

by Javier Bautista

A drug already used to treat breast and ovarian cancer can also significantly delay the progression of prostate cancer...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Dutch court orders sperm donor to request clinics destroy sperm

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels


easyfundraising
amazon

This month in News

  • Popular
  • Recent
20 November 2023 • 3 minutes read

HFEA publishes recommendations for reform of fertility law

13 November 2023 • 2 minutes read

Four BRCA mutation carriers undergo removal of ovaries during C-section 

13 November 2023 • 2 minutes read

Frequent mobile phone use linked to lower sperm count in young men

6 November 2023 • 3 minutes read

Health Council of the Netherlands recommends doubling the 14-day limit on embryo research

30 October 2023 • 2 minutes read

Government to scrap additional IVF screening for same-sex couples

27 November 2023 • 2 minutes read

Research into gene therapy reveals blood cancer risk

27 November 2023 • 2 minutes read

Polish Parliament debates reinstatement of state IVF funding

27 November 2023 • 2 minutes read

Over 100,000 DNA evidence samples must be re-tested in Australia

27 November 2023 • 2 minutes read

Childhood autism associated with infertility in parents

27 November 2023 • 2 minutes read

Unintended consequence of CRISPR/Cas9 genome editing discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856